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Abstract
Background: Almost one-third of Norwegian women aged 25–69 years invited to have a Pap
smear do not attend during the recommended period, and thus constitute a population with high-
risk of cervical cancer (CC). Since the incidence of precancerous lesions of the cervix peak with
occurrence of pregnancies within the same decade in women aged 25 to 35 years of age,
antepartum care presents an opportunity to offer a Pap smear thereby increasing the coverage of
the programme. The study objective was to describe the effect of the antepartum Pap smear on
the coverage of a cytological CC screening programme.
Methods: Among 2 175 762 women resident in Norway in 31.12.1996, all women who gave birth
in 1996–7 were identified from the Medical Birth Registry of Norway. Attendance to the cervical
cancer screening was assessed by linkage to the Cytology Registry separately for the pregnant and
non-pregnant women cohorts. The results were stratified by age, history of previous Pap smear
and history of invitation to the CC screening programme. Logistic regression was used to estimate
the relative probabilities of having a Pap smear adjusted for age, screening history, and time since
invitation, for pregnant and non-pregnant women, respectively.
Results: 69% of the pregnant women had a Pap smear during one year of follow-up since beginning
of the pregnancy with the majority taken during the antepartum period. Irrespectively of age or
history of having a Pap smear, pregnant women were 4.3 times more likely to have a Pap smear
during follow-up compared to non-pregnant women. 63.2% of the pregnant women had a smear as
response to the invitation letter compared to 28.7% of the non-pregnant women, OR = 2.1 (95%
CI 1.9 to 2.4). As an indication of "over-screening", 5397 pregnant women (57.8%) with a smear
shortly before the start of follow-up also had a new Papsmear, compared to 83 023 (32.3%) in non-
pregnant.
Conclusion: Pap smear screening during pregnancy increases the coverage of the CC screening
programme. The contribution of the antepartum Pap smear to "over-screening" exists but its effect
is modest in countries where women on average become pregnant after the start of recommended
age of screening.
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Background
Early detection of cervical cancer (CC) has reduced the
mortality and morbidity of cervical cancer worldwide [1],
and it has been reported that both organised and oppor-
tunistic Pap smear taking has lowered incidence rates of
CC [2]. However, the importance of obtaining and main-
taining a high coverage within the target population has
been unanimously recognised [3-8] and several studies
support the observation that the decrease in incidence
rates is more evident in countries with organised screen-
ing programmes [5,9-11].
The Norwegian co-ordinated CC screening programme
was introduced in 1995 and 71% of the women 25–69
years of age in Norway had a Pap smear in 1998 to 2000
[12]. More than 50% of the CC cases diagnosed however
among the remaining group of non-participants, consti-
tuting a population at high-risk of cervical cancer [13].
To minimize the costs of early detection of CC for society,
only women without a normal Pap smear in a three years
period are identified from the registry files and are invited
to be screened [12]. Not all women attend following the
invitation; in a Swedish study it was reported that non-
attendance to cervical screening was positively associated
with time-consuming and economical barriers [14].
The peak age of incidence of pre-cancerous lesions of the
cervix peaks with the occurrence of pregnancies in the age
range 25–35 [15,16]. From this perspective, antepartum
care presents an opportunity to offer a Pap smear to
women who otherwise might not go for routine health
check-ups, and a means to increase coverage of the pro-
gramme. Screening of this population can however cause
"over-screening" given many of these women might have
had a Pap shortly before the start of the pregnancy. Under-
standing the potential differences in the actual pattern of
Pap smear taking activity among pregnant and non-preg-
nant women would help public health policy makers to
recognise conflicting attitudes towards screening and to
evaluate the effect of antepartum Pap smear as a routine
activity.
The objective of this study is to describe the pattern of Pap
smear taking activity and to estimate the impact of Pap
smear screening in pregnant women on the overall cover-
age of the cervical cancer screening programme.
Methods
Subjects
All women resident in Norway in 31.12.1996 were identi-
fied from the Population Register. Women born before
1900, diagnosed with invasive cervical cancer or under-
went hysterectomy before 1996, died in 1997, or had
inadequate data for estimating the pregnancy duration
were excluded (N = 39 707). The final study population
consisted of 2175762 females and the personal identifica-
tion number (PIN), a unique 11 digit code, identified the
subjects.
The Norwegian co-ordinated CC screening programme
A thorough description of the CC Screening programme is
provided elsewhere [12]. Briefly, the Screening pro-
gramme in Norway is built around the Cytology Register,
which was established in 1992 to administrate the CC
screening programme in Norway. It is mandatory to regis-
ter PIN, date and result of every single Pap smear diag-
nosed in the country, irrespective of age of the woman, the
nature of the health service (private/public) or the indica-
tion of the Pap smear. The PIN is used as a key for linkage
between the Population and the Cytology Registry in
order to identify all 25–69 year old women without a nor-
mal Pap smear during a period of three years, which is the
recommended screening interval in Norway. From 1995
every women without a Pap smear in the period was iden-
tified on a monthly basis and they received personal invi-
tations to participate. In this way, the opportunistic
screening was integrated into the organised programme.
To date information on more than six million Pap smears
is available from the register.
The Medical Birth Registry of Norway
Established in 1967, the Medical Birth Registry of Norway
(MBRN) was organised to conduct epidemiological sur-
veillance of birth defects and other perinatal health prob-
lems in Norway aiming at prevention, as well as health
services related to pregnancy, childbirth and the neonatal
period, aiming at quality assurance. MBRN routinely reg-
isters the PIN and demographic information on the
mother and the father, mother's health before and during
pregnancy, including chronic diseases, complications dur-
ing pregnancy and delivery as well as information on the
infant, including birth defects and other perinatal prob-
lems.
Linkage between study population, MBRN and the Cytology Register
The PIN was used to gather information about pregnan-
cies from the MBRN and previous Pap smears from the
population-based Cytology Register for each subject.
From the MBRN records all 116 810 women who gave
birth (or had abortion after the 16th gestation week) in
1996–7 in Norway (N = 121 400) were identified with
information about exact date of birth, duration of the
pregnancy, details about pregnancy outcome, multiple
offspring, birth weight, and information on previous
pregnancies. When there was more than one pregnancy
registered per women for the period 1996–7 (2615
women had two and four women had three consecutive
records during two years period) the first was included.BMC Health Services Research 2007, 7:10 http://www.biomedcentral.com/1472-6963/7/10
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When there was more than one offspring per birth (1904
twins, 58 triples and 2 women had 4 offspring) we used
information about the first born. For 105 818, women the
date of the last menstruation was available and used as the
beginning of the antepartum period. For 10 992 women
(9.4%) this information was missing and beginning of the
pregnancy period was estimated by subtracting from date
of birth 41 weeks if birth weight was > 3400 gram, 40
weeks if 3200–3400 gram, 39 weeks if 2800–3000 gram,
38 weeks if 2600–2800 gram, 37 weeks if 2400–2600
gram, 36 weeks if 2200–2400 gram, 35 weeks if 2000–
2200 gram, 34 weeks if 1800–2000 gram, 33 weeks if
1600–1800 gram, 32 weeks if 1400–1600 gram, 31 weeks
if 1200–1400 gram, 30 weeks if 1000–1200 gram, 29
weeks if 800–1000 gram, 28 weeks if 600–800 gram, 27
weeks if 400–600 gram.
For each study subject we identified the date and the diag-
noses of the Pap smears from the Cytology Register. Sub-
jects who received an invitation letter from the Cancer
Registry of Norway were identified, together with the post-
ing date of the invitation letter.
Study cohorts
We categorised the following three mutually exclusive
cohorts, within the study population:
1. Pregnant women cohort (Cpreg): subjects giving birth dur-
ing the period ± 3 month from the date 31.12.1996. T0 is
the date denoting the start of the follow-up. For subjects
within the pregnant women cohort, T0 was the date when
the antepartum period started, estimated individually for
each subject as described above.
2. Reference cohort (Cref): subjects who neither gave birth
nor were pregnant during this calendar period respective
to the follow-up period of the pregnant women e.g. from
01.01.1996 to 31.12.1997. For the Reference cohort, T0,
the date marking the start of the follow-up was randomly
chosen for each subject from the same calendar period as
for the Cpreg.
3. Mixed cohort: all other subjects in the study population
who gave birth in 1996–7 but were not included in the
Cpreg.
Pregnant women and reference cohort were followed up
for one year (since T0) in the Cytology Register for Pap
smears. To identify the pattern of attendance to screening
for each subject, time since last Pap smear before T0 was
identified and stratified as the last Pap smear taken 1, 2, 3
or > 3 years earlier. To evaluate the response to the invita-
tion letter, we identified subjects who received an invita-
tion to screening and stratified analyses by the assessed
time since the invitation was mailed in relation to T0, i.e.
24 to 2 months prior to T0, one month prior to 3 months
after the T0, more than three months after the T0.
Statistical analyses
The Kaplan-Meier method was used to estimate the cumu-
lative probability of having a Pap smear since T0.[17]
We used unconditional logistic regression to compare the
odds of having a Pap smear within 12 month after inclu-
sion in the study for Cref and Cpreg. Odds ratios (OR) with
95% confidence intervals (95% CI) were estimated both
crude and adjusted for age, screening history and time
since invitation.
Results
Altogether, 24 297 women were assigned to the Cpreg, 2
060 118 to the Cref and 91 347 to the mixed cohort. For the
three cohorts, age distribution, history of the Pap smear
and history of the invitation are given in Table 1. 44% of
the Cref had Pap smears during the three years before T0
compared to 78 % among the Cpreg, reflecting the wider
age span in the Cref (all female population) compared to
Cpreg or mixed cohort (women of reproductive age). When
only women 15 to 49 years of age were analysed, the pro-
portion having had smears in the Cref was 65% (data not
shown). The occurrence of a Pap smear within one year
after T0 was assessed separately for the Cref and Cpreg (Table
2). Overall, the proportion of women with Pap smears in
the  Cpreg was three times higher (68.7%) than the Cref
(20.8%).
Only women 15 to 44 years of age were included in the
stratified analyses by Pap smear history, invitations and
Kaplan-Meier analyses for estimating cumulative proba-
bility for having a Pap smear since T0. (Figure 1). By the
end of the follow-up of one year, 31.6% of the Cref had a
smear compared to 67.8% of the Cpreg. The linear increase
of the cumulative probability of the Pap smear is an
expected pattern for the screened population in Norway
indicating the appropriate selection of the Cref for current
study.
Compliance with the recommended screening interval of 
three years
80% of the Cpreg and 46% of the Cref women with a Pap
smear 2–3 years prior to T0 and next Pap smear within one
year were classified as those who were following the rec-
ommendations. 76.2% of the Cpreg and 23.1% of the Cref
women women with a smear more seldom than recom-
mended screening interval had a Pap smear within one
year. 57.8% of Cpreg and 32.3% of the Cref women with a
smear taken shortly before and after T0, were classified as
"over-screened".BMC Health Services Research 2007, 7:10 http://www.biomedcentral.com/1472-6963/7/10
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Attendance to the screening following invitation letter
When invitation was mailed close to T0, defined as 4
months, from one month prior to T0 to three months after
T0, 74.6% of Cpreg had a Pap smear in during one year of
follow-up, compared to 37% of the Cref.
Pregnant women were almost 5 times more likely to have
a Pap smear within one year of T0 compared to the non-
pregnant women, crude OR = 4.7 (95% CI 4.6 to 4.8).
After adjusting for age, time since last Pap smear and time
since invitation, this estimate was somewhat lower,
adjusted OR = 4.3 (95% CI 4.2 to 4.4) (Table 3). Women
who had the last Pap smear more than 3 years since T0 had
a smaller probability of a new Pap smear during the next
one year compared to women who had a last smear taken
within one year of T0, irrespectively of the pregnancy sta-
tus, adjusted OR = 0.76 (95% CI 0.75 to 0.77). When this
estimate was limited to Cpreg, the OR was 2.6 (95% CI 2.4
to 2.8), compared to OR of 0.73 (95% CI 0.72 to 0.74) for
the  Cref  only. Compared to the non-pregnant women,
pregnant women were 2.1 times more likely (95% CI 1.9
to 2.4) to have a Pap smear following the invitation letter
if the latter was mailed close to the beginning of T0, com-
pared to the non-pregnant women.
Discussion
We found that smear taking activity during pregnancy in
Norway was high, with 69% of pregnant women having
had a Pap smear during one year of follow-up. Most of the
Pap smears from pregnant women were taken during the
antepartum period, within 4 months from the start of the
pregnancy, and therefore they will be further referred as
antepartum Pap smears. Norwegian guidelines state that
1st trimester antepartum Pap is recommended given no
normal smear was taken during the period of 2,5 years
prior to the visit [16]. This recommendation is given
regardless of age because the average 1st full-time pregnant
Norwegian woman is 29 years old and should already
been participating at the screening. However, 58% of
pregnant women with a smear taken shortly before had
also an antepartum Pap, reflecting the real-life situation,
indicating poor adherence to the guidelines.
Effect of an antepartum Pap smear to the coverage
Compared to non-pregnant women, pregnant women
were 4.3 times more likely to be screened by Pap smear
during one year period, irrespectively of their age or
screening history. As much as 76% of the pregnant
women without a smear in three years prior to start of
Table 1: Baseline characteristics of the Norwegian female population* in 1996 by pregnancy status, age, history of Pap smear and 
invitation to the cervical cancer screening programme
Pregnancy status
Reference cohort 2 060 118 (%) Pregnant cohort 24 297 (%) Mixed cohort 91 347 (%)
Age-groups
< 14 445 928 (21.7) 18 (0.07) 11 (0.01)
15–19 125 039 (6.1) 1688 (7.0) 4090 (4.5)
20–24 130 147 (6.3) 6087 (25.0) 20 103 (22.1)
25–29 127 742 (6.1) 9112 (37.5) 34 809 (38.1)
30–34 131 081 (6.4) 5555 (22.9) 23 530 (25.8)
35–39 144 959 (7.0) 1653 (6.8) 7756 (8.5)
40–44 146 978 (7.1) 178 (0.7) 1024 (1.1)
45–49 149 296 (7.2) 6 (0.02) 24 (0.03)
50–69 394 224 (19.1) - -
70+ 267 724 (13.0) - -
Time since last Pap smear
before T0
0–12 months 441 735 (21.4) 9342 (38.4) 36 318 (39.8)
13–24 months 278 490 (13.5) 5934 (24.4) 23 304 (25.5)
25–36 months 181 158 (8.8) 3662 (15.1) 13 113 (14.4)
> 36 months 1 158 735 (56.2) 5359 (22.1) 18 612 (20.4)
Time since invitation
No invitation 1 567 788 (76.1) 18 374 (75.6) 75 393 (82.5)
24–2 months prior to T0 229 417 (11.1) 2596 (10.7) 989 (1.1)
1 months prior-3 months after T0 132 981 (6.5) 2256 (9.3) 3524 (3.9)
> 3 months after T0 129 932 (6.3) 1071 (4.4) 11 441 (12.5)
* 39 707 were excluded because they were either born before 1900, diagnosed with invasive cervical cancer and/or underwent hysterectomy 
before 1996, died in 1997 or had inadequate data for estimating duration of the pregnancyBMC Health Services Research 2007, 7:10 http://www.biomedcentral.com/1472-6963/7/10
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pregnancy had a smear in follow-up compared to 23% of
the non-pregnant women. This large difference can par-
tially be explained by the fact that more women in age of
15–24 years were included into the Reference cohort and
therefore, should not have been screened at all. The age
issues were taken into account by estimating the risk of a
smear (adjusted for pregnancy status, age, or invitation)
for women without the smear in three years period and
for women who had smear shortly prior to the start of the
study. It was somewhat surprising to observe that women
without a smear within the last three years were less likely
to have a smear compared to women who were screened
lately, OR = 0.76. This figure can be explained by the
observation that women with frequent smear taking activ-
ity were more likely to continue such a pattern, whereas
women who had a smear taken rarely or never, were less
likely to have a smear in the near future. One can postu-
late that one of the most important obligations of an
organized CC screening programme is to minimise the
proportion of women without a smear: and as a conse-
quence, this risk estimate should eventually increase. As
an example, pregnant women who had a last Pap smear
more than three years prior to the start of the study, were
2.6 times more likely to have a smear in one year com-
pared to women with a smear shortly before start of the
study. The comparative figure for the non-pregnant
women was 0.73. Together with the fact that pregnant
women showed a higher probability of a favourable
response to smear taking by invitation letter than non-
pregnant women OR = 2.12 (95% CI 1.89 to 2.38) it
implies that Pap smear in pregnancy increases the cover-
age of the programme.
Elucidating as to why almost two-thirds of non-pregnant
women aged 15–44 years with an invitation letter did not
have Pap smear, and why there was a three times higher
attendance rate among pregnant women compared to
non-pregnant women is important. Possibly an explana-
tion lies in the relatively high work load of the women:
they are usually either studying, have just joined the work
force, have established a family, already have small chil-
dren to tend to, or carry out a combination of these duties.
The need for a regular check up for precursors of cervical
cancer could be given less priority in such demanding/
real-life settings. This explanation is in line with a Swedish
study, where Eaker concluded that non-attendance to cer-
vical cancer screening is rather practically rooted.[18] A
study from the U.S. identified no effect of either patient or
physician reminders on Pap smear completion, while
patients with a chronic illness had a three times higher
Table 2: Proportion of women with Pap-smear during one year follow-up by age, history of Pap smear and invitation to the cervical 
cancer screening programme
Women with Pap smear(s) in follow-up of 12 months
Reference cohort N (%) Pregnant cohort N (%)
Age-groups
< 14 1449 (0.3) 14 (77.8)
15–19 24 181 (19.3) 1115 (66.1)
20–24 44 720 (34.4) 4261 (70.0)
25–29 45 268 (36.3) 6349 (70.0)
30–34 44 844 (34.2) 3725 (67.1)
35–39 47 182 (32.6) 1097 (66.4)
40–44 48 445 (33.0) 120 (67.4)
45–49 49 775 (33.3) 3 (50.0)
50–69 95 905 (24.3) -
70+ 14 056 (5.2) -
Time since last Pap-smear* before T0
0–12 months 83 023 (32.3) 5397 (57.8)
13–24 months 59 021 (36.9) 4289 (72.3)
25–36 months 47 100 (46.0) 2909 (79.5)
> 36 months 65 496 (23.1) 4072 (76.2)
Time since invitation*
No invitation 185 991 (33.2) 12 732 (69.4)
24–2 months prior to T0 26 664 (25.0) 1737 (67.0)
1 months prior-3 months after T0 26 455 (37.4) 1683 (74.6)
> 3 months after T0 15 530 (23.7) 515 (48.1)
* age-groups 15–44 onlyBMC Health Services Research 2007, 7:10 http://www.biomedcentral.com/1472-6963/7/10
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probability of Pap smear completion,[19] indicating that
access to health care is a lesser issue for those with chronic
diseases.
Pap smear screening among women before screening age
Only 32% of the pregnant women were < 25 years old and
expected to be not screened due to young age. Women
aged 15–19 had Pap smears in follow-up period more sel-
dom than women aged 25–29 years, OR = 0.53. However,
the probability of a smear was 66.1 % for pregnant
women compared to 19.3% for non-pregnant women
indicating that antepartum Pap contributed to increased
screening among young women. In absolute terms, 1129
pregnant women aged 15 to 19 years had a smear during
the one-year period. If all pregnant women in this young
age group would have had a smear, the consequent
number would have been 1706 compared to 25630 non-
pregnant young women. It is clear that other factors than
pregnancy seems also relevant in explaining the Pap
smear-taking activity among young women. It should be
remembered that a sexually transmitted virus, human
papilloma virus, is responsible for developing pre-inva-
sive cervical lesions and CC [20,21]. Pregnant women
irrespective of age therefore represent a population with a
past or current exposure to sexually transmitted infec-
tions. However, many mild dysplastic cervical lesions are
subjected to regress, as we have shown in our previous
study on young women [22], suggesting that mass-screen-
ing in young ages is unwarranted.
Does Antepartum Pap smear contribute to "over-
screening"?
Altogether 32% of non-pregnant and 58% of pregnant
women were classified as "overscreened", as defined by
repeated Pap-smears in short period of time, emphasizing
the fact that pregnant women taking an antepartum Pap
cannot be solely the reason for the frequent screening
observed. Further, the overall proportion of pregnant
women in the population is small: expressed in the abso-
lute numbers as much as 83 023 of non-pregnant com-
pared to 5397 pregnant women underlines that the
antepartum Pap does not substantially constitute to the
overall number of extra smears taken.
In the current study in assessing the effect of pregnancy on
coverage only we did not consider the possibility that Pap
Cumulative probability for Pap smear since T0 for women in age of 15–44 years, for the Reference and Pregnant women  cohorts by Kaplan Meieranalyses Figure 1
Cumulative probability for Pap smear since T0 for women in age of 15–44 years, for the Reference and Pregnant women 
cohorts by Kaplan Meieranalyses. Y-axes refer to the proportion of women with Pap smear and X -axes refer to time in 
months from the start of follow-up. The increase of proportion of women with Pap smear during follow-up time is depicted 
separately for Pregnant women cohort (light grey line) and for the Reference cohort (black line).BMC Health Services Research 2007, 7:10 http://www.biomedcentral.com/1472-6963/7/10
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smears taken shortly before the start of the follow-up were
abnormal, and as defined, that they should be followed
up soon after with a Pap smear. Nor did we consider that
the onset of clinical symptom(s) leading to a new Pap
smear. These are relevant concerns that we cannot appro-
priately address in this study design. However, there are
no strong reasons to suspect large difference in the two
cohorts in these respects. Taking into consideration that
the proportion of abnormal Pap smear is low in the pro-
gramme: approx. 86% of all the smears are normal, and
any existing differences in the distribution of abnormal
smears in the pregnant and non-pregnant women are
likely to be only weakly affect the estimates of coverage.
It is natural combine the antepartum visits with the distri-
bution of the health education among women and several
authors demanding the routine antepartum smear [23,24]
in order to improve diagnosis of the CIN. However, the
decision on recommending Pap smears for all pregnant
women should be based on information on the accuracy
of the antepartum Pap to diagnose underlying pre-inva-
sive lesion, the impact on coverage and on the mean ages
of pregnancy in given country.
Conclusion
Several studies have been performed to assess the value of
a Pap smear collected during the antepartum and/or post-
partum period. Conclusions regarding the necessity of
routine Pap smear(s) during pregnancy are often missing
or, sometimes contradictory, reflecting that information
on availability or history about cervical cancer screening is
often unavailable. This registry linkage study has been
conducted to estimate the effect of Pap smear during preg-
nancy on the coverage, and our study suggests that the
provision of Pap smears to all pregnant women in Norway
will increase the coverage of the programme. The contri-
bution of such an action on over-screening and screening
among young women is likely to be modest in the country
where in the average, women become pregnant after the
recommended age of screening.
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Table 3: Probability for Pap smear within one year since T0. Crude and adjusted odds ratios (OR) and 95% confidence intervals (CI) 
were estimated by logistic regression
Probability for Pap smear within 12 month since T0
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15–19 0.53 0.52–0.54
20–24 0.95 0.94–0.97
25–29 1 ref.
30–34 0.91 0.89–0.92
35–39 0.85 0.84–0.87
40–44 0.88 0.87–0.90
Time since last Pap-
smear*
0–12 months prior to T0 1r e f .
13–24 months prior to T0 1.22 1.20–1.24
25–36 months prior to T0 1.77 1.75–1.80
> 36 months prior to T0 0.76 0.75–0.77
Time since invitation*
No invitation 1 ref.
24–2 months prior to T0 0.91 0.89–0.92
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after T0
2.12 1.89–2.38
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